InMed Pharmaceuticals Inc.
INM
$2.12
-$0.23-9.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.94M | 4.92M | 4.83M | 4.96M | 4.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.94M | 4.92M | 4.83M | 4.96M | 4.60M |
| Cost of Revenue | 3.24M | 3.33M | 3.12M | 3.39M | 3.50M |
| Gross Profit | 1.71M | 1.60M | 1.71M | 1.57M | 1.10M |
| SG&A Expenses | 6.56M | 6.07M | 6.11M | 5.92M | 5.80M |
| Depreciation & Amortization | 212.90K | 214.90K | 217.40K | 219.40K | 219.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.86M | 13.01M | 12.60M | 12.22M | 12.73M |
| Operating Income | -7.92M | -8.08M | -7.77M | -7.26M | -8.13M |
| Income Before Tax | -8.16M | -8.30M | -7.91M | -6.81M | -7.67M |
| Income Tax Expenses | -- | 7.10K | 7.10K | 7.10K | 7.10K |
| Earnings from Continuing Operations | -8.16 | -8.31 | -7.91 | -6.82 | -7.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.16M | -8.31M | -7.91M | -6.82M | -7.68M |
| EBIT | -7.92M | -8.08M | -7.77M | -7.26M | -8.13M |
| EBITDA | -7.71M | -7.87M | -7.55M | -7.04M | -7.91M |
| EPS Basic | -9.48 | -12.32 | -13.97 | -14.04 | -26.57 |
| Normalized Basic EPS | -5.93 | -7.69 | -8.72 | -8.76 | -16.60 |
| EPS Diluted | -9.48 | -12.32 | -13.97 | -14.04 | -26.57 |
| Normalized Diluted EPS | -5.93 | -7.69 | -8.72 | -8.76 | -16.60 |
| Average Basic Shares Outstanding | 3.91M | 2.90M | 2.29M | 1.98M | 1.53M |
| Average Diluted Shares Outstanding | 3.91M | 2.90M | 2.29M | 1.98M | 1.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |